ALEXION PHARMACEUTICALS INC.

In News

JCR’s third deal with Alexion gives rights to AAV capsids - BioWorld MedTech

BioWorld MedTech - Jul 09, 2025

AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial - BioPharma Dive

BioPharma Dive - Jul 24, 2025

Novartis Says Alexion's 'Block The Cause' Ads Are False - Law360

Law360 - Oct 21, 2025

Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (g - Yahoo Finance

Yahoo Finance - Aug 07, 2025

Alexion Owes Another $181M for Lack of Commercially Reasonable Efforts in Milestone Earnout Case, Chancery Rules - Law.com

Law.com - Jun 12, 2025

AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters

Reuters - Apr 17, 2025

AstraZeneca Accused of Stifling Biosimilar Competition for Rare Disease Drug - PYMNTS.com

PYMNTS.com - Apr 17, 2025

AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News

Bloomberg Law News - Apr 17, 2025

JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines - Business Wire

Business Wire - Jul 08, 2025

AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug - Fierce Biotech

Fierce Biotech - Feb 06, 2025

Big Pharma Still Sees Value In Cell And Gene Therapy’s Next Wave - Citeline News & Insights

Citeline News & Insights - Oct 09, 2025

10 Pharmaceutical Companies in France to Know - Built In

Built In - Mar 18, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment